{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:38:51Z","timestamp":1786523931439,"version":"build-2736575974"},"reference-count":18,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background: Elranatamab, a bispecific antibody targeting BCMA and CD3, has demonstrated clinical activity in relapsed\/refractory multiple myeloma. Real-world evidence regarding infectious complications and supportive care remains limited. We evaluated the early clinical activity, safety profile, infectious complications, and supportive care practices associated with relapsed\/refractory multiple myeloma (RRMM). This study represents one of the first multicenter real-world evaluations of elranatamab in T\u00fcrkiye. Methods: This multicenter retrospective study included 87 patients with relapsed\/refractory multiple myeloma treated with elranatamab. Clinical characteristics, treatment responses, immune-mediated toxicities, infectious complications, and supportive care practices were assessed. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were evaluated. Multivariable analyses were performed to identify factors associated with treatment response and clinical outcomes. Results: At 3 months, ORR was 47.1% in the ITT population, 54.7% in the mITT population, and 83.7% among evaluable patients; corresponding 6-month ORRs were 31.0%, 42.2%, and 81.8%, respectively. The high proportion of patients without landmark response assessments primarily reflected insufficient follow-up, early death, or disease progression. Elevated LDH remained independently associated with lower response probability and inferior clinical outcomes. Cytokine release syndrome (CRS) occurred in 69% of patients, with grade \u2265 3 events in 5.7%, whereas immune effector cell-associated neurotoxicity syndrome (ICANS) was infrequent (4.6%) and no grade \u2265 3 events occurred. Grade \u2265 3 infections occurred in 39% of patients, including CMV events requiring antiviral treatment in 24.1%. No HBV reactivation occurred among patients receiving antiviral prophylaxis. Median PFS and OS were 8.1 and 10.6 months, respectively. Conclusions: Elranatamab demonstrated early clinical activity and a manageable safety profile in a heavily pretreated real-world RRMM population. Infectious complications, including CMV events, remained clinically relevant, emphasizing the importance of supportive care. Longer follow-up is needed to characterize long-term outcomes.<\/jats:p>","DOI":"10.3390\/jcm15166232","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T07:57:26Z","timestamp":1786521446000},"page":"6232","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Elranatamab in Relapsed\/Refractory Multiple Myeloma: A Multicenter Real-World Study from T\u00fcrkiye"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3886-8900","authenticated-orcid":false,"given":"Asl\u0131","family":"Bozdemir","sequence":"first","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0757-9206","authenticated-orcid":false,"given":"Sibel","family":"Hac\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2073-1949","authenticated-orcid":false,"given":"G\u00fcls\u00fcm","family":"Akg\u00fcn \u00c7a\u011fl\u0131yan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3292-8519","authenticated-orcid":false,"given":"Nevin","family":"Alayvaz Aslan","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8876-2848","authenticated-orcid":false,"given":"S\u00fcleyman Utku","family":"Uzun","sequence":"additional","affiliation":[{"name":"Division of Epidemiology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay\u0131han","family":"Kara","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku","family":"Iltar","sequence":"additional","affiliation":[{"name":"Division of Hematology, Akdeniz University Hospital, Antalya 07070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orhan Kemal","family":"Y\u00fccel","sequence":"additional","affiliation":[{"name":"Division of Hematology, Akdeniz University Hospital, Antalya 07070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00dcnal","family":"Ata\u015f","sequence":"additional","affiliation":[{"name":"Division of Hematology, Akdeniz University Hospital, Antalya 07070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selin","family":"Arslan Kirezli","sequence":"additional","affiliation":[{"name":"Division of Hematology, Akdeniz University Hospital, Antalya 07070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali \u0130hsan","family":"Gemici","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dokuz Eyl\u00fcl University Hospital, \u0130zmir 35340, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130nci","family":"Alacac\u0131o\u011flu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Dokuz Eyl\u00fcl University Hospital, \u0130zmir 35340, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9059-4740","authenticated-orcid":false,"given":"Mustafa Kemal","family":"Yeniay","sequence":"additional","affiliation":[{"name":"Division of Hematology, \u0130zmir City Hospital, \u0130zmir 35530, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oktay","family":"Bilgir","sequence":"additional","affiliation":[{"name":"Division of Hematology, \u0130zmir City Hospital, \u0130zmir 35530, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3237-320X","authenticated-orcid":false,"given":"Zehra","family":"Narl\u0131 \u00d6zdemir","sequence":"additional","affiliation":[{"name":"Division of Hematology, TOBB ET\u00dc Faculty of Medicine Hospital, Ankara 06560, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Handan","family":"Haydaro\u011flu \u015eahin","sequence":"additional","affiliation":[{"name":"Division of Hematology, Gaziantep University Hospital, Gaziantep 27310, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5581-8104","authenticated-orcid":false,"given":"Ay\u015fe","family":"Uysal","sequence":"additional","affiliation":[{"name":"Division of Hematology, F\u0131rat University Hospital, Elaz\u0131\u011f 23119, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zekeriya","family":"Aks\u00f6z","sequence":"additional","affiliation":[{"name":"Division of Hematology, F\u0131rat University Hospital, Elaz\u0131\u011f 23119, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Tu\u011fba","family":"G\u00fcven","sequence":"additional","affiliation":[{"name":"Division of Hematology, Adana City Hospital, Adana 01370, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kemal","family":"Ayg\u00fcn","sequence":"additional","affiliation":[{"name":"Division of Hematology, \u0130zmir Atat\u00fcrk Training and Research Hospital, \u0130zmir 35360, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atakan","family":"Tekinalp","sequence":"additional","affiliation":[{"name":"Division of Hematology, Necmettin Erbakan University Faculty of Medicine Hospital, Konya 42080, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Division of Hematology, Sanko University Hospital, Gaziantep 27090, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cansu","family":"Atmaca Mutlu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Buca Seyfi Demirsoy Training and Research Hospital, \u0130zmir 35390, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00f6khan","family":"Pekta\u015f","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mu\u011fla Training and Research Hospital, Mu\u011fla 48000, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ozan","family":"Salim","sequence":"additional","affiliation":[{"name":"Division of Hematology, Akdeniz University Hospital, Antalya 07070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nil","family":"G\u00fcler","sequence":"additional","affiliation":[{"name":"Division of Hematology, Pamukkale University Hospital, Denizli 20070, T\u00fcrkiye"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/ejh.70151","article-title":"Salvage Therapy in Multiple Myeloma with Prior T-Cell Engager Exposure: Talquetamab, Elranatamab or Teclistamab in Combination with Pomalidomide","volume":"116","author":"Vesole","year":"2026","journal-title":"Eur. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41408-024-01200-w","article-title":"Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: Results of the French compassionate use program on behalf of the IFM","volume":"14","author":"Malard","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1080\/14796694.2026.2662504","article-title":"Real-world treatment patterns and outcomes of patients with multiple myeloma initiating elranatamab: Results from the ALTITUDE-1 and ALTITUDE-2 retrospective cohort studies","volume":"22","author":"Banerjee","year":"2026","journal-title":"Future Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_7","unstructured":"National Cancer Institute (2017). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1002\/ajh.27422","article-title":"Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management","volume":"99","author":"Rajkumar","year":"2024","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1038\/s41375-019-0435-7","article-title":"Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy","volume":"33","author":"Gandhi","year":"2019","journal-title":"Leukemia"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1182\/blood-2025-136","article-title":"Real-world outcomes with elranatamab in multiple myeloma: A multi-center analysis from the United States multiple myeloma immunotherapy consortium","volume":"146","author":"Portuguese","year":"2025","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/S2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in Relapsed or Refractory Multiple Myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: A pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: A systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Marneni, N., Lessans, S., Dholaria, B., Sengsayadeth, S., Biltibo, E.A., Patel, V., Bhaskar, S., Jayani, R., Mohan, S., and Kishtagari, A. (2026). Flat dose intravenous immunoglobulin primary infection prophylaxis in multiple myeloma patients on BCMA and GPRC5D bispecific antibody therapy: The Vanderbilt experience. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1721820"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Benda, M., Reimann, P., Willenbacher, W., Gunsilius, E., Weisel, K., Strassl, I., Krauth, M.T., Knop, S., Winder, T., and Steiner, N. (2026). Infectious toxicities associated with bispecific antibodies and CAR-T cells in multiple myeloma: A systematic review. Ann. Hematol., Epub ahead of print.","DOI":"10.1007\/s00277-026-07140-8"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/jha2.70189","article-title":"Baseline Cytomegalovirus Immunoglobulin G Levels Predict Reactivation in Patients with Multiple Myeloma Receiving Elranatamab","volume":"6","author":"Kondo","year":"2025","journal-title":"eJHaem"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"102851","DOI":"10.1016\/j.jiac.2025.102851","article-title":"Cytomegalovirus reactivation with severe lymphopenia during elranatamab treatment: A case series in patients with triple-class refractory multiple myeloma","volume":"32","author":"Kitamura","year":"2026","journal-title":"J. Infect. Chemother."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6232\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:22:14Z","timestamp":1786522934000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/16\/6232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":18,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["jcm15166232"],"URL":"https:\/\/doi.org\/10.3390\/jcm15166232","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]}}}